Project Grant R21NS144529
Award Date 9/1/26
Completion Date 8/31/28
Dollars Obligated $454K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02111, USA
Similar Awards
- The National Institute of Neurological Disorders and Stroke (NINDS), part of the Department of Health and Human Services National Institutes of Health, awarded $153,560 to the Broad Institute, Inc. (doing business as Broad Institute of MIT and Harvard) on December 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The award funds research examining how excitatory neurons regulate interneuron fate, position, and survival during...
- The National Institute of Neurological Disorders and Stroke awarded the University of Virginia $490,593 on September 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to investigate the role of growth differentiation factor 11 (GDF11) in neurodevelopmental disorders. The research examines GDF11 as a molecular hub involved in abnormal brain function across multiple genetically distinct neurodevelopmental disorders. The first...
- The National Institute of Neurological Disorders and Stroke, part of the Department of Health and Human Services, awarded Boston Children's Hospital $577,573 on September 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The award funds functional validation of candidate genes implicated in refractory focal epilepsy, with emphasis on mosaic variants in mTOR pathway genes and non-mTOR genes such as SLC35A2. Boston Children's...
- The National Institute of Neurological Disorders and Stroke awarded the University of Massachusetts Medical School $460,625 on September 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) for development of AAV-mediated gene silencing to treat hypomyelination with atrophy of the basal ganglia and cerebellum (H-ABC), a rare, progressive leukodystrophy caused by mutations in the TUBB4A gene. The research develops an AAV9 vector...
- The National Institute of Neurological Disorders and Stroke awarded Seattle Children's Hospital $516,175 on September 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to investigate the role of MN1 in central nervous system developmental malformations. The research compares MN1 null and C-terminal truncation mutant mice to characterize cerebellar and cerebral cortex phenotypes associated with MN1 C-terminal truncation syndrome,...
- The National Institute of Neurological Disorders and Stroke awarded Emory University $575,485 on February 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to investigate the role of the BCL11A gene in neuron function and neurological disease. The award funds research examining how BCL11A, a zinc-finger transcription factor, contributes to intellectual disability, autism spectrum disorder, epilepsy, schizophrenia, and...
- The National Institute of Neurological Disorders and Stroke awarded Cincinnati Children's Hospital Medical Center $445,500 on September 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to conduct genetic dissection of the rasopathy gene NF1 and MAPK pathway activation in cortical cell fate. The research investigates mechanisms regulating early stages of gliogenesis from cortical progenitors using mouse models. Three specific...
- The National Institute of Neurological Disorders and Stroke awarded Miami University $539,920 on September 5, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to investigate how TSC1 loss disrupts Purkinje neuron axon initial segment organization and cerebellar function in autism spectrum disorder. The research examines the cellular mechanisms by which TSC1 deletion in Purkinje neurons alters axon initial segment function and...
- The National Institute of Neurological Disorders and Stroke awarded $551,888 to Massachusetts General Hospital on August 19, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to investigate the causes and consequences of tRNA ligation defects in neurodegeneration. The research examines how genomic GGC repeat expansions drive neurodegenerative diseases through polyglycine protein aggregation. The study biochemically characterized...
- The National Institute of Neurological Disorders and Stroke awarded Massachusetts General Hospital $161,880 on May 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The award funds investigation of TTYH3 protein and its relationship to CLN3 Batten disease, a rare lysosomal disorder affecting approximately 1 in 100,000 live births. The research will develop tools to study TTYH3 in the context of CLN3 disease, including...